To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created

NEWS
Publication
July 14, 2017

Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase. The mathematical model developed in InSysBio, described how exactly such a non-standard composition will accumulate in various tissues of the body.

Slow release of drugs in chemotherapy is an important factor that reduces the toxic effects of active substances on healthy cells, since the simultaneous admission of high concentrations harms the body. The BIND RUS company investigated nanoparticles consisting of a special polymer. The process of particles assembly was designed so that one can control their size and level of saturation with the drug. On the surface of the particles special protein markers that "recognize" receptors on cancer cells were placed. All this allowed to program a site and speed of the content release once nanoparticles were injected into the patient body. Thus, the medication doesn’t hit the blood, and can be slowly released into the tissues of the affected organ, providing a prolonged effect with lower doses of chemotherapy.

Absolutely unique properties made nanoparticles in some sense unpredictable for pharmacologists. This has complicated the selection of doses for clinical trials and future therapeutic applications. Unlike most drugs, the pharmacokinetics of which is simple and well-studied, the use of nanoparticles forced researchers to consider simultaneously three processes: the distribution of nanoparticles in the body, the distribution of the chemotherapeutic drug and its transition from an encapsulated state into an external environment. Moreover, studies have shown that the high toxicity of the drug effects on the speed distribution of the nanoparticles. The developers of new therapies encountered the question: how to predict a compound concentration in a particular organ for such a complex system?

The solution was found by means of mathematical modeling conducted by Evgeny Metelkin group from the InSysBio company. The team worked with a huge number of unique experimental data provided by BIND RUS, including several types of nanoparticles, programmed for different profiles of release. For modeling such a system, was needed information about the change of drug concentration in vitro and the same data for different tissues and organs, measured in rodents. Collaboration of the theoretical and experimental groups helped to develop the first prototype of the decision-making system for nanoparticles to optimize the release profile and the selection of doses for the new class of drugs.

https://doi.org/10.1016/j.jconrel.2017.06.006

May 2025
MoTuWeThFrSaSu
   
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
1. 15 May 2025 15:07 15th InSysBio’s Annual Internal Scientific Meeting InSysBio held its 15th Annual Internal Scientific Meeting. The Meeting traditionally passed in warm, friendly atmosphere and the discussion was efficient and uniting.
16
17
18
19
20
21
1. 21 May 2025 16:55 InSysBio to take part in PAGE 2025 InSysBio announces its participation in the Thirty-third PAGE Meeting which is to be held from 4-6 June, 2025, at the Thessaloniki Concert Hall in Thessaloniki, Greece. InSysBio team is going to present its QSP modeling services & software to optimize drug development at the Booth #10 in the upper foyer and 2 posters in frames of the Meeting
22
23
24
25
26
27
28
29
30
1. 30 May 2025 15:23 InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics The new article “Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data” has been recently published in CPT: Clinical Pharmacology & Therapeutics
31
 
Upcoming Events
04.06
InSysBio to take part in PAGE 2025
Tags
Latest News
30.05
InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics
15.05
15th InSysBio’s Annual Internal Scientific Meeting
09.04
InSysBio to release a new version of LikelihoodProfiler.jl
31.03
InSysBio to launch Immune Response Template version 3.7.0 for QSP modeling
19.03
InSysBio announces its collaboration with discoveric bio alpha